SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 201 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,502 | -66.0% | 12,510 | -25.1% | 0.00% | – |
| Q2 2023 | $22,090 | -32.7% | 16,700 | -13.1% | 0.00% | – |
| Q1 2023 | $32,805 | -45.7% | 19,223 | +1.8% | 0.00% | – |
| Q4 2022 | $60,413 | -42.5% | 18,892 | -11.5% | 0.00% | – |
| Q3 2022 | $105,000 | +18.0% | 21,350 | 0.0% | 0.00% | – |
| Q2 2022 | $89,000 | -53.6% | 21,350 | -10.7% | 0.00% | – |
| Q1 2022 | $192,000 | +20.0% | 23,897 | +12.7% | 0.00% | – |
| Q4 2021 | $160,000 | -19.6% | 21,213 | -3.5% | 0.00% | – |
| Q3 2021 | $199,000 | -18.4% | 21,976 | +8.2% | 0.00% | -100.0% |
| Q2 2021 | $244,000 | -30.9% | 20,312 | -28.0% | 0.00% | 0.0% |
| Q1 2021 | $353,000 | +37.4% | 28,192 | +69.6% | 0.00% | 0.0% |
| Q4 2020 | $257,000 | +54.8% | 16,620 | -5.1% | 0.00% | – |
| Q3 2020 | $166,000 | +3.1% | 17,505 | -1.8% | 0.00% | -100.0% |
| Q2 2020 | $161,000 | +35.3% | 17,827 | -4.3% | 0.00% | – |
| Q1 2020 | $119,000 | – | 18,634 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |